IN THE CLAIMS:

Please amend the claims as follows:

Claim 1 (Original): A reagent for diagnosis and/or prognostic evaluation of carcinoma, which comprises an anti-P-LAP antibody as an active ingredient.

Claim 2 (Original): The reagent as claimed in Claim 1, wherein the carcinoma is gynecological carcinoma.

Claim 3 (Original): The reagent as claimed in Claim 2, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.

Claim 4 (Currently Amended): The reagent as claimed in ~~any one of Claims 1 to 3~~ Claim 1, wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.

Claim 5 (Currently Amended): The reagent as claimed in ~~any one of Claims 1 to 3~~ Claim 1, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.

Claim 6 (Original): A method for determination of P-LAP which is a prognostic factor in carcinoma, which comprises

(a) a step of contacting carcinoma tissues obtained from carcinoma patients with an anti-P-LAP antibody, and

(b) a step of measuring the intensity of the specific antigen-antibody reaction between P-LAP present in the carcinoma tissues and anti-P-LAP antibody.

Claim 7 (Original): The method as claimed in Claim 6, wherein the carcinoma is gynecological carcinoma.

Claim 8 (Original): The method as claimed in Claim 7, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.

Claim 9 (Currently Amended): The method as claimed in ~~any one of Claims 6 to 8~~ Claim 6, wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.

Claim 10 (Currently Amended): The method as claimed in ~~any one of Claims 6 to 8~~ Claim 6, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.

Claim 11 (Original): A method for prognostic evaluation of carcinoma, which comprises

(a) a step of contacting carcinoma tissues obtained from carcinoma patients with an anti-P-LAP antibody,

(b) a step of measuring the intensity of the specific antigen-antibody reaction between P-LAP present in the carcinoma tissues and anti-P-LAP antibody, and

(c) a step of correlating the intensity of the specific antigen-antibody reaction with prognosis of carcinoma.

Claim 12 (Original): The method as claimed in Claim 11, wherein the carcinoma is gynecological carcinoma.

Claim 13 (Original): The method as claimed in Claim 12, wherein the gynecological carcinoma is endometrial endometrioid adenocarcinoma, cervical carcinoma or ovarian carcinoma.

Claim 14 (Currently Amended): The method as claimed in ~~any one of Claims 11 to 13~~ Claim 11, wherein the anti-P-LAP antibody is an anti-human P-LAP antibody.

Claim 15 (Currently Amended): The method as claimed in ~~any one of Claims 11 to 13~~ Claim 11, wherein the anti-P-LAP antibody is an anti-human P-LAP polyclonal antibody.

Claim 16 (Original): An immunoassay kit for determination of the amount of P-LAP present in carcinoma tissues obtained from carcinoma patients, which comprises an anti-P-LAP antibody and a marker enzyme for determination of the amount of the P-LAP bound to the anti-P-LAP antibody.